全文获取类型
收费全文 | 274054篇 |
免费 | 23475篇 |
国内免费 | 7778篇 |
专业分类
耳鼻咽喉 | 1729篇 |
儿科学 | 5355篇 |
妇产科学 | 2309篇 |
基础医学 | 31415篇 |
口腔科学 | 4147篇 |
临床医学 | 36612篇 |
内科学 | 41414篇 |
皮肤病学 | 2141篇 |
神经病学 | 18129篇 |
特种医学 | 27937篇 |
外国民族医学 | 48篇 |
外科学 | 21608篇 |
综合类 | 40122篇 |
现状与发展 | 14篇 |
一般理论 | 26篇 |
预防医学 | 14687篇 |
眼科学 | 5562篇 |
药学 | 22897篇 |
116篇 | |
中国医学 | 10177篇 |
肿瘤学 | 18862篇 |
出版年
2024年 | 762篇 |
2023年 | 3930篇 |
2022年 | 7966篇 |
2021年 | 10786篇 |
2020年 | 9864篇 |
2019年 | 9684篇 |
2018年 | 9500篇 |
2017年 | 9726篇 |
2016年 | 10077篇 |
2015年 | 10000篇 |
2014年 | 16362篇 |
2013年 | 16875篇 |
2012年 | 14572篇 |
2011年 | 16146篇 |
2010年 | 13663篇 |
2009年 | 13505篇 |
2008年 | 13435篇 |
2007年 | 14281篇 |
2006年 | 12994篇 |
2005年 | 12294篇 |
2004年 | 10663篇 |
2003年 | 9055篇 |
2002年 | 6959篇 |
2001年 | 6717篇 |
2000年 | 5570篇 |
1999年 | 4970篇 |
1998年 | 3890篇 |
1997年 | 3522篇 |
1996年 | 3431篇 |
1995年 | 3171篇 |
1994年 | 2754篇 |
1993年 | 2396篇 |
1992年 | 2052篇 |
1991年 | 1727篇 |
1990年 | 1463篇 |
1989年 | 1314篇 |
1988年 | 1206篇 |
1987年 | 967篇 |
1986年 | 714篇 |
1985年 | 886篇 |
1984年 | 911篇 |
1983年 | 574篇 |
1982年 | 676篇 |
1981年 | 585篇 |
1980年 | 504篇 |
1979年 | 442篇 |
1978年 | 352篇 |
1977年 | 274篇 |
1976年 | 314篇 |
1975年 | 212篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
4.
5.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
6.
ObjectiveEach pulmonary segment is an anatomical and functional unit. However, it is fundamentally difficult to precisely distinguish every pulmonary segment using the conventional pulmonary intersegmental planes from computed tomography images. Building arteriopulmonary segments is likely to be an effective way to identify pulmonary segments.MethodsThe thoracic computed tomography images of 40 patients were collected. The anatomic structures of interest were extracted in the transverse, sagittal, and coronal planes using the semi-automated segmentation tools provided by Amira software. The intrapulmonary vessels were subsequently segmented and reconstructed. The distributions of the pulmonary arteries, veins, and bronchi were observed. In patients with pulmonary masses, the mass was also reconstructed.ResultsThe three-dimensional reconstructed images showed the branches of the pulmonary artery ramified up to their eighth order covering the entire lung as well as evident intersegmental gaps without pulmonary arteries. The segmental artery was closely accompanied by the segmental bronchi in 486 pulmonary segments (90% of total number of segments). The size and spatial location of the pulmonary mass within a pulmonary segment were also clearly visible.ConclusionsDemarcation of arteriopulmonary segments can be used to precisely distinguish every pulmonary segment and provide its detailed anatomical structure before pulmonary segmentectomy. 相似文献
7.
8.
9.
10.
《Clinical microbiology and infection》2022,28(8):1120-1125
ObjectivesOur aim was to evaluate the effect of the updated European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group 2019 definitions for invasive pulmonary aspergillosis (IPA) on patient classification and the related all-cause 12-week mortality.MethodsIn this retrospective cohort study from our tertiary care centre, we reclassified patients with haematological malignancy who underwent bronchoalveolar lavage between 2014 and 2019 for suspected IPA using the novel EORTC 2019 criteria. We performed receiver operating characteristic curve analysis to define the optimal cut-off for positive PCR and galactomannan and present survival analyses and their possible association with these diagnostic criteria through post hoc comparisons with log rank and Cox regression.ResultsFrom 323 episodes of suspected IPA in 282 patients, 73 were reclassified: 31 (42.5%) from possible to probable IPA, 5 (6.8%) from EORTC criteria not met to probable IPA, and 37 (50.7%) from EORTC criteria not met to possible IPA. Probable IPA increased therefore 11.1% (64/323, 19.8% to 100/323, 30.9%), mostly due to positive PCR (31/36, 86.1%). There was no difference in mortality between newly defined possible and probable IPA (log rank p = 0.950). Mortality was higher in probable cases with lower cycle thresholds (Ct values) versus higher Ct values (p = 0.004). Receiver operating characteristic curve analysis showed an optimal Ct value cut-off of 36.8 with a sensitivity of 75% (95% CI 64.9%–85.1%) and a specificity of 61.7% (95% CI 53.5–69.9) for 12-week mortality.DiscussionThe new EORTC criteria led to 11.1% more probable IPA diagnoses, mostly due to Aspergillus PCR. Restricting positive PCR to below a certain threshold might improve the discrimination of the new EORTC IPA categories for mortality. 相似文献